Home › Funds › Global X › Global X HealthTech ETF
Fund family: Global X · Filed by Global X Funds (CIK 1432353) · SEC series S000069056
Ticker: HEAL (C000220776)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 352 with, 1 against, 2 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 1 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Global X’s manager page (125,623 ballot items across 92 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Global X | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 73.6% | 329 | 91.0% | 107,427 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 21.0% | 2,383 |
Each ballot item this fund voted is set against the votes of the other Global X funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Global X funds on 14 items (19.7% of the 71 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Global X funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. | 2026-05-07 | Election of Directors: Kevin A. Lobo | Against | FOR — 15 of 15 Global X funds | Against | Passed (calculated), 91.2% support |
| DexCom, Inc. | 2026-05-27 | To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025. | Against | FOR — 17 of 18 Global X funds | Against | Approved, 88.3% support |
| DexCom, Inc. | 2026-05-27 | To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Dr. Euan Ashley | Against | FOR — 15 of 16 Global X funds | Against | — |
| DexCom, Inc. | 2026-05-27 | To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Richard Collins | Against | FOR — 15 of 16 Global X funds | Against | — |
| DexCom, Inc. | 2026-05-27 | To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Steven Altman | Against | FOR — 15 of 16 Global X funds | Against | Elected, 95.1% support |
| Insulet Corporation | 2026-05-20 | To approve, on a non-binding, advisory basis, the compensation of certain executive officers. | Against | FOR — 12 of 13 Global X funds | Against | Passed (calculated), 92.0% support |
| Insulet Corporation | 2026-05-20 | Elect TImothy C. Stonesifer | Withhold | FOR — 10 of 11 Global X funds | Against | — |
| ResMed Inc. | 2025-11-19 | Ratify our selection of KPMG LLP as our Independent registered public accounting firm for the fiscal year ending June 30, 2026. | Against | FOR — 9 of 10 Global X funds | Against | — |
| IQVIA Holdings Inc. | 2026-04-23 | Election of Directors: James A. Fasano | Against | FOR — 8 of 9 Global X funds | Against | — |
| IQVIA Holdings Inc. | 2026-04-23 | Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2026. | Against | FOR — 8 of 9 Global X funds | Against | Approved, 90.9% support |
| ResMed Inc. | 2025-11-19 | Election of director to serve until our 2026 annual meeting and until their successors are elected and qualified. The nominee for election as director at the 2025 annual meeting is: Christopher DelOrefice | Against | FOR — 8 of 10 Global X funds | Against | — |
| ResMed Inc. | 2025-11-19 | Election of director to serve until our 2026 annual meeting and until their successors are elected and qualified. The nominee for election as director at the 2025 annual meeting is: Desney Tan | Against | FOR — 8 of 10 Global X funds | Against | — |
| ResMed Inc. | 2025-11-19 | Election of director to serve until our 2026 annual meeting and until their successors are elected and qualified. The nominee for election as director at the 2025 annual meeting is: Karen Drexler | Against | FOR — 8 of 10 Global X funds | Against | — |
| ResMed Inc. | 2025-11-19 | Election of director to serve until our 2026 annual meeting and until their successors are elected and qualified. The nominee for election as director at the 2025 annual meeting is: Ronald Taylor | Against | FOR — 8 of 10 Global X funds | Against | — |
Download all 14 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 77.2% of this fund’s 355 such votes could be given a sector; the other 81 (22.8%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 206 | 1 | 0.5% |
| Technology | 39 | 0 | 0.0% |
| Consumer Discretionary | 29 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 219 | 0 |
| Audit-related | 38 | 0 |
| Say-on-Pay | 31 | 0 |
| Compensation | 26 | 0 |
| Corporate Governance | 26 | 1 |
| Capital Structure | 16 | 0 |
| Extraordinary Transactions | 2 | 0 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| IQVIA Holdings Inc. | April 23, 2026 | $2M | 13 | 1 |
| ResMed Inc. | November 19, 2025 | $2M | 15 | 0 |
| GE HealthCare Technologies Inc. | May 7, 2026 | $2M | 10 | 0 |
| DexCom, Inc. | May 27, 2026 | $2M | 14 | 0 |
| Oscar Health, Inc. | June 4, 2026 | $2M | 10 | 0 |
| Intuitive Surgical, Inc. | April 30, 2026 | $1M | 13 | 0 |
| Veeva Systems Inc. | June 17, 2026 | $1M | 10 | 0 |
| Waystar Holding Corp. | June 1, 2026 | $939,211 | 6 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| April 23, 2026 | IQVIA Holdings Inc. | If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposal | For | Against |
359 ballot items at 40 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Global X HealthTech ETF (HEAL) voted at 40 shareholder meetings of 39 companies, on 359 ballot items in all. Where management made a recommendation, the fund followed it on 99.2% of the items and voted against it 1 time. Its most frequent area of disagreement was corporate governance (1 of its votes against management). It voted on 1 shareholder proposal. It voted FOR the board's own proposals less often than Global X's funds as a whole (73.6% against 91.0%). It voted differently from most Global X funds on 14 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Global X’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.